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EDITORIAL REVIEW
Potential role of platelet-activating factor in renal
pathophysiology
Recently a new class of lipid chemical mediators, acetylated
alkyl phosphoglycerides, with a wide spectrum of biological and
pharmacological activities, has been identified and recognized
as the most potent "autacoid" known so far. The first mediator
of this class discovered was the platelet-activating factor (PAF)
[1]. PAF was originally identified as a product released by
antigen-stimulated IgE sensitized rabbit basophils [1]. The
active component of PAF is l-0-alkyl-2-sn-glyceryl-3-phospho-
rylcholine [2, 3]. Since its structural definition, PAF has also
been termed PAF-acether [2] or AGEPC [3]. PAF has a unique
spectrum of diverse and potent biological activities. Aside from
inducing aggregation and degranulation of platelets [1], PAF
produces contraction of smooth muscle [4, 5], has negative
inotropic and arrythmogenic cardiac effects [6—8], and stimu-
lates aggregation, chemotaxis and granule secretion in polymor-
phonuclear neutrophils (PMN) [9, 10] and monocytes [11].
Furthermore, PAF induces "in vivo" a systemic hemoconcen-
tration with extravasation of plasma proteins [12, 13], local
leukocyte infiltration [14], edema [15], vasoconstriction [16,
17], vasodilation [17], and increased vascular [16, 18] and
glomerular [19] permeability. Lastly, PAF has a strong
hypotensive action [20—22]. It has been demonstrated that PAF
may be released not only from basophils [1] but, after appro-
priate stimulation, from monocytes-macrophages [23, 24], PMN
[24—26], platelets [27], from endothelial cells [28, 29], and from
several organs including the kidney [30, 31].
Though its precise physiological role has not yet been de-
fined, several studies suggest that PAF has an important func-
tion in the "entangled web" of humoral and cellular effectors of
inflammation and in vascular homeostasis. In this review the
available direct and indirect evidence that PAF exerts a role in
renal physiopathology will be discussed.
In vitro release of PAF from leukocytes, platelets, and
endothelial cells
Henson [32] described a soluble factor that induces liberation
of histamine from platelets. This factor was recovered from the
cell-free supernatant of antigen-stimulated sensitized-leuk-
ocytes. It was proposed that the factor has a function in
leukocyte-platelet communication. Subsequent studies by
Benveniste, Henson, and Cochrane [1] indicated that this newly
discovered mediator in the fluid phase is released by IgE-
sensitized basophils when these cells are stimulated with spe-
cific antigen. The obvious implication was that this factor,
termed PAF because of its ability to stimulate platelets, is
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involved in the pathogenesis of anaphylactic reactions. Rabbit
basophils release PAF through an IgE-dependent mechanism
and do not release PAF when challenged with anaphylatoxin
(C3a or C5a) [30, 33]. Studies on human mixed leukocyte
preparations, containing other types of leukocytes besides
sensitized basophils, showed concomitant PAF release and
basophil degranulation not only after challenge of these cell
preparations with specific antigen but also after challenge with
C5a [30]. Still, the evidence that sensitized human basophils
release PAF on challenge with specific antigen is only indirect.
This evidence consists of the morphological observation of the
interaction between platelets and degranulated basophils [24],
and the demonstration that synacthen, which triggers the same
membrane sites activated by cell-bound reagins, induces the
release of PAF from basophil-enriched preparations but not
from purified PMN or monocytes [24]. However, because the
isolation of a pure population of viable human basophils is
difficult, the attempts to recover PAF from purified human
basophils thus far have failed [33].
Data obtained from in vitro experiments indicate that PAF
can be released from leukocytes in immune complex-mediated
hypersensitivity reactions. PAF was recovered from superna-
tants of mixed leukocyte preparations to which immune com-
plexes had been added [30]. The cells involved in the PAF
release were identified in humans as PMN [9, 24, 26] and
monocytes/macrophages [9, 24], in the rabbit as PMN [9, 34],
and in the rat as macrophages [23]. Phagocytosis by human or
rabbit PMN of C3b or IgG-coated particles, or of immune
complexes prepared at equivalence or in antibody excess, is
also associated with the liberation of PAF; a similar reaction
occurs when PMN are stimulated with native or desarginated
C5a or neutrophil cationic proteins [9, 24]. Adherence of human
monocytes to a plastic surface was found to increase the rate
and amount of release of PAF during phagocytosis of opsonized
particles or immune complexes [25]. This phenomenon may be
explained by the observation that adherence of monocytes
enhances the expression of Fc, C3b, and C3d surface receptors,
which, in turn, facilitates the process of phagocytosis. C5a
causes receptor-mediated release of PAF from PMN, but it fails
to have a similar action on monocytes [25]. Chignard et al [27]
reported that human platelets also release PAF during aggrega-
tion induced by lonophore A23187 or thrombin. Lastly, the
results of studies performed in vitro, using endothelial cell
preparations and antibodies directed against antigens (angioten-
sin-converting enzyme; factor VIII of the coagulation system)
expressed on the plasma membrane of endothelial cells, support
the possibility that PAF is released in antibody- and comple-
ment-mediated reactions [28, 35]. Human endothelial cells
release PAF after challenge with lonophore A23 187, angioten-
sin II, and vasopressin [28]. Thrombin induces PAF production
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by human endothelial cells, but not secretion of PAF into the
supernatant buffer [28, 29] unless thrombin is added repeatedly,
or the concomitant generation of PGI2 is pharmacologically
blocked [281. The data reviewed above are consistent with the
hypothesis that nonimmunological stimuli generated during or
independently from hypersensitivity reactions may contribute
to release PAF in vivo.
In vitro release of PAF from renal tissue
When renal tissue samples obtained from rabbits immunized
with peroxidase to evoke an IgE response are challenged with
the same antigen, PAF and histamine were released concomi-
tantly [30]. C5a and C3a anaphylatoxins and neutrophil-derived
cationic proteins were also shown to induce a release of PAF
from rabbit and human renal tissue samples [30]. Pirotzky,
Misumi, and Boullet [36] demonstrated that biologically active
PAF recovered from perfused isolated rat kidneys stimulated
with lonophore A23 187, exhibited the same physicochemical
characteristics that PAF obtained from leukocytes. In acute
serum sickness induced in the rabbit by immunization with
bovine serum albumine (BSA), an active release of PAF was
obtained when renal tissue samples obtained 6 days after BSA
clearance was challenged in vitro with BSA [37]. Blanket al [381
have proposed that the antihypertensive polar renal medullary
lipid (APRL) may have the same structure as PAF. APRL was
originally described by Muirhead et al [391 and was extracted
from murine and rabbit renomedullary interstitial cells.
Pirotzky et a! [40] and Pirotsky and Bidault [41] recently
confirmed that PAF is produced by rat renomedullary cells.
Furthermore, the glomerular fraction isolated from the cortex
of rat kidney was shown to release PAF when stimulated with
lonophore A23187 or incubated at pH 9.5 [40, 41].
The concomitant release of PAF, slow-reacting substance,
histamine, and serotonin has been demonstrated in the renal
venous effluent of isolated rat kidneys perfused with lonophore
A23 187 or with antigen previously used for the immunization of
the rats [31]. The release of PAF from isolated rat glomeruli
[401, tubular cell fraction [401, cultured human glomerular
mesangial and epithelial cells has also been studied (unpub-
lished results), It was found that rat glomeruli release PAF
when challenged with lonophore A23 187, when incubated at pH
9.5 [40], or when stimulated with CSa. The PAF obtained from
glomeruli may originate from resident mononuclear phagocytes
or from endothelial or mesangial cells which are able to release
PAF in culture. In contrast, cultured glomerular epithelial cells
obtained by cloning were unable to produce PAF. The tubular
cell fraction obtained from renal cortex also failed to release
relevant amounts of PAF. This was not due to a defect in the
first step of PAF biosynthesis, namely, the activation of
phospholipase A2 leading to formation of 2-lyso-PAF, but
rather to the absence of a relevant acetyl-transferase activity in
these cells [40]. In contrast the glomerular PAF formation
seems to correlate with acetyl-transferase activity of the
microsomal fraction, which increases after the stimulation with
lonophore A23 187 [40]. This finding indicates that in glomeruli
the acetylation of 2-lyso PAF in position sn-2 by a specific
acetyl CoA transferase may be the central pathway in PAF
formation [40, 42]. The available data on the role of the same
pathway in PAF biosynthesis from renomedullary interstitial
cells are contradictory [40, 42].
Biologic activity of PAF in in vitro systems
Platelets. PAP is the most active platelet-activating agent
thus far described [431. It activates washed rabbit platelets at
concentrations as low as 1 x 10—12 M. For comparison, it may
be noted that the required concentration of ADP is 1 X 106 M.
PAF stimulate guinea pig platelets at concentrations ranging
from 1 x i0 to I x 10—10 M, and human platelets at the
concentration of 1 X iO M. Rat platelets are in contrast,
unresponsive to PAF [43]. PAF causes aggregation and secre-
tory activity in platelets. The two processes differ in sensitivity
and can be dissociated one from another since secretion occurs
before and independently from aggregation [44]. Several studies
indicate that PAF-induced platelet activation is independent of
the cyclo-oxygenase metabolite-mediated pathway [43]. How-
ever, PAF, but not its inactive 2-lyso-derivative (lyso-PAF),
initiates thromboxane B2 (TxB2) synthesis from platelets in
plasma in a dose-dependent manner [45]. When human platelets
are used, it can be shown that PAF induces a stimulation of
TxB2 production in concentrations of 1 X 10-8 M PAF with a
maximal effect at 1 x 16 M, without stirring [46]. Lower
concentration of PAF (1 x l0 M), still active on human
platelet in plasma, are unable to induce TxB2 synthesis. Indo-
methacin, an inhibitor of cyclo-oxygenase, blocks the PAF-
induced TxB2 synthesis, but does not influence the aggregation
or the release reaction of platelets [46]. Rabbit and human
platelets can be specifically densitized by a brief exposure to
PAF, suggesting the existence of a specific recognition unit.
The analysis of the binding of 3H-PAF to human platelets has
shown the presence of unique, saturable high affinity binding
site compatible with the existence of a specific surface receptor
[47]. Though the chemical nature of the binding site has not
been determined, the demonstration that an SDS extract of
human platelet membranes binds 3H-PAF suggests that the
binding site is a protein. Recently, Valone and Johnson [48]
described that PAF modulates the cytoplasmic calcium content
in human platelets. The mobilization of calcium in PAF-stim-
ulated platelets is related to certain early biochemical changes
occurring after receptor activation. Lapetina [49] proposed that
one of these biochemical changes is the degradation of inositol
phospholipids, especially the degradation of phosphatidylinosi-
tol 4-5 biphosphate (PIP2). These phospholipids located at the
cytoplasmic face of the plasma membrane of platelets represent
an important cellular calcium-binding site. The early degration
of PIP2 by PAF is independent of mobilization of cytoplasmic
Ca + and precedes and triggers the phosphatidylinositol cycle
which is secondary to the mobilization of internal platelet Ca +
[49]. These events result in formation of I ,2,diacylglycerol,
which can activate a protein kinase C and induces the formation
of phosphatidic acid that might act as an intracellular Ca +
ionophore, thus causing a further release of Ca from the
dense tubular system. This Ca mobilization may activate
membrane phospholipase A2, which generates arachidonic acid
from the membrane phospholipids with the consequent activa-
tion of the cyclo-oxygenase and/or the lipoxygenase pathways
[49].
Polymorphonuclear neutrophils (PMN) and monocytes. PAP
aggregates purified rabbit and human PMN [9, 10] leading to
nonlytic enzyme release. The PMN aggregation induced by
PAF and the release of azurophil and specific granules [9, 10] as
well as the generation of superoxide [10] are independent but
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concomitant processes. Cytochalasin B potentiates both the
aggregation and the release reaction [9]. PAF also exerts
chemotactic activity on PMN, in the range of 10—10 to 10—6 M
[10] with a minor chemokinetic effect [10]. As seen for
lysosomal enzyme release, both chemotaxis and chemokinesis
are inhibited by higher concentrations of PAF [10]. Rabbit PMN
stimulated with PAF (2 x 10—8 M) in the presence of cytocha-
lasin B release arachidonic acid, phosphatidyicholine, and
phosphatidylinositol [50]. PAF-induced activation of PMN is in
part related to the generation of lipoxygenase-derived metabo-
lites. Rabbit PMN generate LTB4, 5-11- and 5-hydroxy
6,8,11, 14-eicosa-tetraenoic acid (HETE), phosphatidic acid,
but neither thromboxanes nor prostaglandins [50].
Within a few seconds of stimulation with 9. i0 M PAF,
human PMN generate and release LTB4 and 5-HETE [51].
LTB4 acts as a potent activator of PMN and is in part respon-
sible for PAF-induced PMN stimulation in humans. However,
the specific desensitization of PMN after exposure to PAF [9]
and the absence of cross-desensitization with C5a or formyloli-
gopeptides indicate the existence of a specific recognition unit
on their membranes. The analysis of the binding of 3H-PAF by
human PMN is consistent with a receptor-specific interaction
[52].
More recently, it has been demonstrated that human periph-
eral blood monocytes are capable of aggregating in response to
PAF [11]. As for PMN, the aggregation is an active process that
depends on glycolysis and requires the presence of divalent
cations. It has also been reported that PAP is chemotactic for
monocytes and induces the release of enzymes and the gener-
ation of superoxide [11].
These data, obtained from studies performed in vitro are
consistent with the possibility that PAF may be involved in the
recruitment of inflammatory cells (PMN and monocytes) at the
site of inflammation in vivo. PAF might induce leukocyte
aggregation with embolization in the microvasculature and
adherence to endothelial cells with accumulation in the in-
flammed tissue; it might contribute to attract inflammatory cells
into the extravascular spaces acting as chemotactant through
the walls of the vessels. Finally, PAF could be a mediator that
promotes monocyte-platelets, PMN-platelets or monocyte-
PMN interactions.
Smooth and myocardial muscle cells. An additional biologi-
cal activity of PAP is a potent agonistic effect on smooth muscle
cells. Findlay Ct a! [4] showed that PAF induced a dose-
dependent contraction of isolated guinea pig ileum. Similar
spasmogenic effect of PAP has been demonstrated on lung
parenchymal strips of guinea pig [5] and rabbit [53]. The
PAF-induced contraction develops slowly and is followed by
delayed relaxation. Prior exposure to PAF induces specific
desensitization of the tissues to a subsequent PAP challenge,
but not to histamine, acetyicholine, and slow-reacting sub-
stances of anaphylaxis [4—5]. No cross-desensitization exists
between PAP and CSa which also induces a specific desensiti-
zation. PAF-induced contraction of smooth muscle cells is not
prevented by inhibitors of Hi or muscarinic receptors or by
inhibitors of cyclo-oxygenase [53]. In contrast, inhibitors of
lipoxygenase partially prevent PAP-induced contraction but
does not affect the response to histamine or to acetyicholine
[53]. In addition, the sensitivity of smooth muscle cells seems to
be confined to certain organs since PAP does not contract, for
instance, smooth muscle cells of the trachea and large bronchi
[54]. Prancan et a! [55] showed that PAF induces a relaxation of
guinea-pig trachea.
Recent studies on the isolated heart have demonstrated that
PAP induces marked reduction in ventricular contractile force
and coronary blood flow and conduction arrhythmias [6, 7].
Furthermore, PAP exerts a direct effect on guinea pig isolated
papillary muscle. This effect is characterized by: (1) a transient
positive inotropism with an increase of action potential dura-
tion; and (2) a marked negative effect both on inotropism and
action potential. These effects were related to an early Ca
transmembrane influx, followed by a profound inhibition of
Ca + slow channels [8].
Glomerular cells in culture. Schlondorff et al [56] recently
reported a contractile response of cultured rat mesangial cells
alter stimulation with PAF. The contraction is enhanced in the
presence of inhibition of prostaglandin synthesis by indometh-
acm and decreased by the addition of PGE2. The authors
proposed that a feedback mechanism might exist, whereby
enhanced PGE2 production, induced by PAF itself, antagonizes
the contractile action of PAP [56], a mechanism similar to that
suggested for vasoactive agents such as angiotensin II. In
addition, PAF stimulates the release of oxygen radicals by
mesangial cells in a dose-dependent manner [57]. These results
indicate a potential direct effect of PAF on glomerular
homeostasis and a direct role in the pathogenesis of the inflam-
matory reactions that occur in renal glomeruli.
Physiological and physiopathological changes caused by the
systemic or local administration of PAF
The intravenous administration of native or synthetic PAP
causes a dose-dependent thrombocytopenia, neutropenia, and
basopenia in the rabbit [58] and a thrombocytopenia and
neutropenia in the baboon [12], changes in blood elements
associated with hemoconcentration, and an increase in the
plasma levels of PP4 and TxB2 [12, 58]. The thrombocytopenia
and neutropenia are the consequence of intravascular aggrega-
tion of platelets and PMN with subsequent sequestration of
these elements mostly in the microvasculature of the lung [9,
58]. In the rabbit, the intravenous infusion of PAP in doses that
induce thrombocytopenia, produces profound functional alter-
ations of the pulmonary and cardiovascular systems closely
resembling those seen in IgE-mediated systemic anaphylaxis;
these alterations are only partially platelet activation-dependent
[21, 22].
The cardiac and hemodynamic changes consist of early
alterations of the electrocardiogram (ECG) characterized by
variation in heart rate (early bradycardia followed by
tachycardia) and rhythm (conduction arrhythmias) associated
with a consistent depression of the ST segment, a sign of
subendocardial ischemia. All the ECG alterations occur despite
platelet depletion and are completely reversed within 3 to S mm.
The hemodynamic changes induced by PAF are, as described
by Halonen et al [22], platelet-independent and consist of an
early decrease of systolic left ventricular pressure and systolic
and diastolic femoral artery pressure, followed by a transient
increase and, 15 sec later, by a progressive, marked, constant
decrease. A defective venous return was observed in dogs alter
the infusion of PAF as a result of blood maldistribution [59].
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However, the central venous pressure and the right atrial
pressure as well as the right ventricular end-diastolic pressure
markedly increase in rabbits infused with PAF [21, 221 as the
consequence of an increase in pulmonary vascular resistence.
The latter is probably related not only to lung mechanical
changes [211 but also to the massive recruitment of platelets and
PMN in the lung capillary network [9, 58]. These events might
account for a pulmonary "barrage" and mainly depend on the
presence of platelets. The pulmonary "barrage" possibly asso-
ciated with a peripheral pooling leading to reduced venous
return may be responsible for a reduction of left ventricular
filling and consequently of the cardiac output. An additional
mechanism capable of depressing cardiac performance may be
the direct negative inotropic effect of PAF [8]. The observed
increase in heart rate and total peripheral resistence are most
probably due to adrenergic stimulation, probably compensating
the marked hypotension, and/or to a direct spastic effect of PAF
on peripheral arterioles.
Bessin et al [60] reported that after 30 mm of infusion of PAF
in dogs there is a loss, by extravasation, of 43% of the total
plasma volume, with essentially an hypovolemic shock. The
alterations in renal function described by these authors [60] are
similar to those that occur in a situation of shock. PAF infused
intravenously at a dose of 2 pg/kg decreases the creatinine
clearance (—62%), the urine output (—58%), and the para
aminohippuric acid (PAH) clearance (—72%) [60]. The reduc-
tion of PAH clearance indicates that renal blood flow is mark-
edly depressed by PAF infusion. As reported in cardiac failure
and shock, PAF induces a rise in proximal sodium reabsorption
[60] probably as a consequence of the disproportion between
the decrease in glomerular filtration and that in renal bloodflow.
Similar but transient reduction of renal blood flow occurs in
rabbits in the first 30 mm of infusion of 1.5 g/kg of PAF. In
addition to the functional changes, structural endothelial lesions
leading to increased capillary wall permeability with formation
of interstitial edema are observed in the heart as well as in the
lung. The extent of endothelial cell damage is most severe in the
heart. While in the heart the PAF-provoked endothelial pathol-
ogy is not associated with the presence of inflammatory cells, a
massive accumulation of degranulated platelets and PMN oc-
curs in the lung.
After perfusion with PAF the following changes are seen in
glomeruli: Structurally there are massive accumulation, aggre-
gation, and degranulation of platelets and PMN in the capillar-
ies (Fig. 1); the endothelial changes are characterized by
swelling and an increase in number and size of fenestrae (Fig.
2). The latter changes are particularly evident in platelet-
depleted rabbits; in addition, there is a binding to the glomerular
capillary wall of cationic proteins (Fig. I inset) released first by
PAF-stimulated platelets and later by PMN, with a concomitant
loss of fixed negative charges [19]. An increased permeability of
the glomerular capillary wall, shown by transient proteinuria, is
observed [19]; this functional abnormality is independent of the
release of vasoactive amines from platelets. This latter finding
would favor the interpretation that neutralization of fixed neg-
ative charge by cationic proteins is a primarily responsible for
the PAF-induced increase in glomerular capillary wall perme-
ability [19]. In acute serum sickness a similar mechanism may
be instrumental in the entrapment of circulating immune com-
plexes in glomerular structures.
However, in the experiments mentioned above the possibility
has not been excluded that PAF may have a direct action on
glomerular permeability. In fact, it has been shown that PAF is
on a molar basis, 1,000 to 10,000 times more potent than
histamine in increasing cutaneous vascular permeability [16]. A
possible mechanism is a primary stimulation of endothelial
cells.
The local administration of PAF in organs other than the
kidney has been shown to induce not only an increase in
vascular permeability but also an active local recruitment and
activation of inflammatory cells [14]. A preliminary study
indicates that similar events occur in the kidney after the
injection of PAF in the renal artery (unpublished results).
Release of PAF associated with immunopathological
reactions
The intravascular release of PAF was first demonstrated in
the anaphylactic hypersensitivity reaction [61]. Pinckard, Fan,
and Hanahan [61] recovered PAF from plasma of IgE-sensitized
rabbits immediately following the administration of antigen.
These authors demonstrated that the release of PAF into the
circulation precedes the activation and sequestration of plate-
lets [61]. In addition, it was found that during systemic
anaphylaxis in the rabbit, platelets became specifically insensi-
tive to stimulation with PAF [62]. Lastly, as described in the
previous section, the intravenous administration of PAF to
rabbits, faithfully reproduces the condition of systemic
anaphylaxis [21, 22]. All these data strongly suggest that
basophil-derived PAF is a most important mediator of anaphy-
lactic reactions.
However, several in vivo observations are consistent with
the notion that PAF has a pathogenic role in immune complex-
mediated hypersensitivity reactions. First, in rabbits intrave-
nously injected with preformed immune complexes or with C5a
[9], a release of PAF from PMN is followed by the development
of thrombocytopenia and neutropenia. Second, PAF has been
implicated in the pathogenesis of acute serum sickness in the
rabbit [37]. The acute glomerulonephritis and arteritis, charac-
teristic for this condition, are related to the accumulation in
affected tissues of immune complexes, most of them presum-
ably originally formed in the circulation.
Several studies have shown that in experimental serum
sickness the deposition of immune complexes in vascular
structures is associated with increased vascular permeability
induced by basophil degranulation and release of mediators
from platelets [46]. It has been shown that platelets are directly
involved in the pathogenesis of acute serum sickness by a
complement-independent leukocyte-dependent mechanism
[63]. This mechanism has been related to the release of PAF
from IgE-sensitized basophils [1].
In acute serum sickness the release of PAF seems to be
generated by an IgE-dependent basophil degranulation [37] and
not by circulating immune complexes in antigen excess. In fact,
the formation of immune deposits in glomeruli is preceded by
intravascular release of PAF, concomitant with an in vivo
degranulation of basophils. The role of PAF in the formation of
immune deposits in glomeruli is suggested by the following
observations: First, rabbits with high levels of immune com-
plexes, but no in vivo degranulation of basophils and release of
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Fig. 1. Electron micrograph of the kidney of a
rabbit injected in the abdominal aorta with 0.6
g of synthetic PAF. The animal was
sacrificed 20 mm after the injection. There is
an accumulation of partly or completely
degranulated platelets (P) in a glomerular
capillary lumen, swelling of the endothelial (E)
and of the visceral epithelial (EP) cells, and
focal disappearance of the foot processes.
Polymorphonuclear leukocyte: PMN. (X 3400)
Inset: Immunofluorescence micrograph
showing the localization of platelet cationic
proteins in the glomerular capillary walls in a
rabbit injected with synthetic PAF (from [191).
(x500)
PAF, do not develop glomerulonephritis; second, in rabbits
developing the disease the platelets become specifically desen-
sitized to the action of PAF [37], and third, as in the experi-
ments of in vivo infusion of PAF, intravascular release of PAF
is accompanied by platelet activation, glomerular localization of
platelet-derived cationic proteins and focal neutralization of
fixed anionic sites (unpublished results).
In a study designed to test the possibility that the localization
of immune complexes in glomeruli result from the neutraliza-
tion of fixed anionic sites, Barnes and Venkatachalam [64] have
reported that polyethyleneimine, an exogenous polycation en-
hances the subepithelial localization of preformed immune
complexes in the rat.
Finally, PAF may be relevant in the cytotoxic hypersensitiv-
ity reactions. An intravascular release of PAF has been dem-
onstrated in two animal models of endothelial cell damage. In
one set of experiments, anti-angiotensin-converting enzyme
antibodies were intravenously administered to rabbits [35]. The
antibodies bound to angiotensin-converting enzyme present on
the surface of lung endothelial cells. Concomitant with comple-
ment fixation, redistribution of angiotensin-converting enzyme,
and acute endothelial damage, PAF became detectable in the
plasma. PAF release was also found in PMN-depleted rabbits
injected with anti-angiotensin-converting enzyme antibodies.
Based on this and other observations, it was proposed that
endothelial cells may contribute to an intravascular PAF release
[35]. This interpretation was later strengthened by studies
performed in vitro [28, 35]. The release of PAF was also studied
in hyperacute kidney allograft rejection in the rabbit [65].
Transplantation of a kidney allograft into a presensitized rabbit
resulted in the immediate binding of transplantation antibodies
and complement to the endotheium of glomerular and
peritubular capillary, an event that was followed by the appear-
ance of PAF in the venous effluent of the transplant. Subse-
quent to the PAF release, an influx of platelets, and thereafter
of PMN, was noted. Binding of platelet- and PMN-derived
cationic proteins to glomerular anionic sites was also demon-
strated. This finding might have a pathogenic significance in the
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development of glomerular injury in this experimental condition
[65].
In few patients with systemic lupus erythematosus (SLE), a
human disease characterized by immune complex pathology,
PAF was demonstrated in the plasma after destruction of
acid-labile PAP inhibitors. In these patients cationic proteins
released in the circulation by PMN [66] and platelets were
bound to the glomerular capillary walls (unpublished results).
An intravascular release of PAP was also shown in a variety
of immunological or non-immunological diseases characterized
by disseminated intravascular coagulation (unpublished results).
Conclusion: What is the biological sign j/lcance of PAF and
what is its relevance in renal physio-pathology?
PAF is a mediator of cell-to-cell communication. The speci-
ficity of its action is related to the function of the target cells. Its
physiologic activity is most probably mainly confined at the
level of cell-to-cell interaction by potent humoral and cellular
Fig. 2. Electron micrograph of kidney of a
rabbit depleted of platelets as described in [22]
that received an intra-aortic injection of 0.6 ,.tg
of synthetic PAF. The animal was sacrificed 20
mm after the injection. There is an increase in
number and size of the fenestrae of the
glomerular capillary wall endothelium (E).
PMNs are present in the lumen of glomerular
capillaries. (x 5000)
inactivators. At the vascular level PAP may influence locally
the relationship between the endothelial cells, which are able to
produce PAP, and the smooth muscle cells sensitive to PAP
action, with a local vasoconstriction (spasmogenic effect) or
vasodilation (relaxation). PAP may directly influence the per-
meability of vessels as a result of its action on endothelial cells,
or inducing release of secondary mediators. PAP may influence
the interaction of the endothelium with platelets and leukocytes.
When released in vascularized tissue, PAP may mediate, at
least in part, the local vasoactive component of the inflamma-
tory reaction, the recruitment of inflammatory cells and plate-
lets and the release of their phlogistic content at the site of the
inflammation. Thus, PAP may have a part in the induction of
tissue injury in immunologically-mediated processes. A moder-
ately increased concentration of PAP seems only transiently
detectable in the systemic circulation in acute inflammation
involving a single organ or apparatus because PAP is rapidly
inactivated by binding to target cells and by humoral inhibitors.
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and tissue at the site of the inflammatory reaction, where this
mediator is released as, for example, demonstrated in hypera-
cute renal allograft rejection [65].
Lastly, PAF may be regarded as a mediator of shock when a
massive intravascular release occurs in a brief period of time;
experimentally, a condition that mimics systemic anaphylaxis is
induced by intravenous infusion of PAP.
The role of PAF in renal physiopathology has not yet been
clearly defined. The kidney tissue (glomerular and medullary
cells) is able to synthetize PAP and an increased plasma
concentration of PAF has been demonstrated in im-
munopathological reactions involving the kidney. At the
glomerular level PAP may stimulate the contraction of mesan-
gial cells influencing their function [56] and increasing the
permeability of the glomerular capillary wall directly or through
secondary mediators [19]. Since PAP is able to exert well-
defined biological activities both in vitro and in vivo, it is quite
possible that PAF may have a role not only in glomerular
inflammatory reactions but also in more generic vascular phe-
nomena influencing blood pressure and vascular permeability
locally or systemically.
These hypotheses, however, remain to be proven and must
be considered with caution for the following reasons: First, the
amount of PAP released in vitro from kidney or kidney-derived
cells may not reflect its effective in vivo potential since most of
the available data are obtained with artificial stimulation (that
is, lonofore A23 187 or pH 10.6) and in the absence of plasma
inhibitors of PAF (acetylhydrolase and binding to plasma pro-
teins) and in the absence of cellular binding sites (that is,
platelets, PMN). Second, the techniques used to determine the
amount of PAF in plasma are relatively insensitive since they
require extraction, chromatography, and biological tests. Thus,
the estimation of PAP present in physiological and pathological
conditions may not reflect the real PAP concentration. Third,
potent inhibitors of PAP are physiologically present in the
plasma. Therefore, the amount of PAF detected in the systemic
circulation probably does not reflect the concentration that PAP
may reach at the site of production. Fourth, the available data
concerning alterations of renal function induced by intravenous
injection of PAF [60] are mainly the consequence of systemic
hemodynamic changes. In addition, all the experiments per-
formed in vivo by systemic or local administration of PAP
mainly explore the effects induced by an acute increase in PAP
levels. It is obvious that these experimental conditions investi-
gate the pathological potential of PAF but hardly reflect phys-
iologic conditions.
The considerations listed above indicate that convincing
evidence for a direct regulatory role of PAF on renal physiology
is still missing. Nonetheless, there are a few findings suggesting
that we should keep our minds open to the possibility that such
a role indeed exists. First, minimal amounts of PAP have been
detected in the circulation of normal individuals after a 25-fold
concentration of blood, but not in the circulation of anephric
patients [67]. This observation is consistent with a physiological
role of kidney in PAF production as also suggested by the
detection of PAP in the urine of normal subjects [68]. The
absence of PAP in the plasma of anephric patients, however,
could also be due to the uremia. Second, PAF has been
detected in the blood effluent from the renal vein of unclipped
kidney, in rats rendered hypertensive with the Goldblatt tech-
nique [69]. The results of these experiments could be inter-
preted as indicating that PAF influences systemic blood pres-
sure or renal hemodynamics. Plasma inhibitors would keep
minimal the levels of PAP in systemic circulation preventing the
manifestation of pathologic effects.
It is evident that this scattered information does not provide
a complete picture of the role of PAP on renal function in
physiological and pathological conditions. The recent identifi-
cation of receptor-specific inhibitors of PAF promises to extend
our knowledge. However, we should not underestimate the
difficulty of these studies. It is more and more evident that PAF
exerts its multiple functions in association with other mediators
characterized by similar or complementary effects. Thus, the
task to identify which effect pertains to PAP alone may not be
easy. It is clear that further studies are needed to establish the
precise role of PAP on renal physiopathology.
GIOVANNI CAMUSSI
Torino, Italy
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